F S&P 500
5,244.50 -1.75 (-0.03%) F Dow Jones
39,634.00 -8.00 (-0.02%) F Nasdaq
18,256.75 +1.75 (+0.01%) E-mini Russell 2000 Index Futur
2,069.10 +1.20 (+0.06%) Petróleo
77.93 -0.33 (-0.42%) Oro
2,365.50 -9.50 (-0.40%)
Talphera, Inc. (TLPH)
Talphera, Inc.
1850 Gateway Drive
Suite 175
San Mateo, CA 94404
United States
650 216 3500
https://talphera.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 15
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Vincent J. Angotti | CEO & Director | 1.02M | N/D | 1968 |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder & Chief Medical Officer | 752.4k | N/D | 1963 |
| Mr. Raffi Mark Asadorian | Chief Financial Officer | 683.26k | N/D | 1969 |
| Mr. Anil N. Dasu | Chief Engineering Officer | 478.09k | N/D | 1963 |
Descripción
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Talphera, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
